Celesa Therapeutics is set to present data from its global Phase 3 trial of deupirfenidone at the European Respiratory Society (ERS) Congress in Barcelona next month. The SURPASS-IPF study, registered as NCT07284602, compares deupirfenidone at 825 mg three times daily against pirfenidone at 801 mg three times daily in approximately 1,100 adults with idiopathic pulmonary fibrosis.
The primary endpoint of the trial is the change from baseline in absolute forced vital capacity at Week 52. Earlier Phase 2b results indicated stabilization of lung function over at least 26 weeks. The company will also present findings from a Phase 1 drug-drug interaction study assessing co-administration of deupirfenidone and nintedanib, with preliminary data suggesting clinically relevant interactions are unlikely.
Vincent Cottin of Louis Pradel Hospital will outline the SURPASS-IPF trial design during a presentation on September 6 at 8:00 AM CEST. Philip Molyneaux of Imperial College London will discuss the drug-interaction study the following day at 11:05 AM CEST. Both sessions are part of the ERS Congress, scheduled for September 5–9 in Barcelona, Spain.
Deupirfenidone, a deuterated form of pirfenidone, has received Orphan Drug Designation from the U.S. Food and Drug Administration and the European Commission. Idiopathic pulmonary fibrosis, the target indication, is a progressive lung disease with a median survival of two to five years following diagnosis.
